Immunovia AB (IMMNOV) - Medical Equipment - Deals and Alliances Profile
October 2018
43
About the Report
About the Report
Summary
Immunovia AB (Immunovia) is a molecular diagnostics company that offers clinical testing for early diagnosis of pancreatic cancer. The company develops IMMray, a technology platform based on antibody microarray analysis, which can be used in the early diagnosis of cancer, predicting disease progression, and monitoring the therapeutic responsiveness of cancers. Immunovia's IMMray can also be used for biomarker discovery through its discovery tool for proteome scanning. The company also provides IMMray PanCan-d, a blood-based test for the detection of pancreatic cancer. Its therapeutic areas include cancer and autoimmune diseases such as systemic lupus erythematosus. The company collaborates with various cancer centers for conducting clinical evidence studies. Immunovia is headquartered in Lund, Sweden.
Immunovia AB (IMMNOV)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Immunovia AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Immunovia AB, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Immunovia AB, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Immunovia AB, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Immunovia AB, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
Immunovia AB, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Immunovia AB, Medical Equipment, Deal Details 11
Partnerships 11
Immunovia Enters into Research Collaboration Agreement with Linkoping University 11
Immunovia Enters into Agreement with Lund University Diabetes Centre 12
Immunovia Enters into Agreement with University of Michigan Comprehensive Cancer Center 13
Immunovia to Enter into Agreement with National Cancer Institute 14
Immunovia Enters into Agreement with Ramon y Cajal Institute for Health Research 15
Immunovia Enters into Agreement for IMMray 16
Immunovia Partners with Mount Sinai Health System 17
Immunovia Enters into Agreement with University of Liverpool 18
Immunovia Partners with OHSU Knight Cancer Institute 19
Equity Offering 20
Immunovia Raises USD37.3 Million in Private Placement of Shares 20
Immunovia Raises USD3.4 Million in Rights Offering of Shares 22
Immunovia Prices Private Placement of Shares for USD22.3 Million 24
Immunovia Plans to Raise Funds in Public Offering of Shares 25
Immunovia Raises USD7 Million in IPO 26
Immunovia AB-Key Competitors 27
Immunovia AB-Key Employees 28
Immunovia AB-Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Aug 24, 2018: Immunovia interim report, january-june 2018 30
Apr 27, 2018: Immunovia Interim report, January-March 2018 31
Feb 15, 2018: Immunovia Full Year report, January-December 2017 32
Nov 10, 2017: Immunovia Interim report, January-September 2017 33
Aug 23, 2017: Immunovia Interim report January-June 2017 34
Apr 20, 2017: Immunovia Interim report, January-March 2017 35
Feb 15, 2017: Immunovia Financial Statement 2016 36
Corporate Communications 37
Jul 17, 2017: Leading pancreatic cancer expert on early symptoms Professor Stephen Pereira at University College London joins Immunovia's Scientific Advisory Board 37
Legal and Regulatory 38
Jun 28, 2017: Immunovia Establishes US Headquarters, Including CLIA Reference Laboratory, in Boston 38
Product News 39
Sep 17, 2018: New blood test detects early stage pancreatic cancer 39
Jun 21, 2017: Immunovia's IMMray presents biomarkers that differentiates Rheumatoid Arthritis from other autoimmune diseases with 89% accuracy 40
Mar 31, 2017: Edison Issues Update on Immunovia (IMMUNOV) 41
Other Significant Developments 42
Aug 09, 2018: Immunovia's blood-based IMMray biomarker array provides highly accurate diagnosis of non-small cell lung cancer in a new collaborative study 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43
List of Figure
List of Figures
Immunovia AB, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Immunovia AB, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Immunovia AB, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Immunovia AB, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Immunovia AB, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Immunovia AB, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
Immunovia AB, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Immunovia AB, Medical Equipment, Deals by Market, 2012 to YTD 2018 9
List of Table
List of Tables
Immunovia AB, Medical Equipment, Key Facts 2
Immunovia AB, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Immunovia AB, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Immunovia AB, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Immunovia AB, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Immunovia AB, Deals By Market, 2012 to YTD 2018 9
Immunovia AB, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Immunovia Enters into Research Collaboration Agreement with Linkoping University 11
Immunovia Enters into Agreement with Lund University Diabetes Centre 12
Immunovia Enters into Agreement with University of Michigan Comprehensive Cancer Center 13
Immunovia to Enter into Agreement with National Cancer Institute 14
Immunovia Enters into Agreement with Ramon y Cajal Institute for Health Research 15
Immunovia Enters into Agreement for IMMray 16
Immunovia Partners with Mount Sinai Health System 17
Immunovia Enters into Agreement with University of Liverpool 18
Immunovia Partners with OHSU Knight Cancer Institute 19
Immunovia Raises USD37.3 Million in Private Placement of Shares 20
Immunovia Raises USD3.4 Million in Rights Offering of Shares 22
Immunovia Prices Private Placement of Shares for USD22.3 Million 24
Immunovia Plans to Raise Funds in Public Offering of Shares 25
Immunovia Raises USD7 Million in IPO 26
Immunovia AB, Key Competitors 27
Immunovia AB, Key Employees 28
Immunovia AB, Subsidiaries 29
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.